logo

For the Inventor, By the Inventor

Farmingdale, NY, United States of America

Enzo Therapeutics, Inc.


USPTO Granted Patents = 31

% Expired Patents = 16.1



Forward Citations = 158

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Robert Elliot Zipkin (9 out of 13 patents)

silverMedal Sarah Spiegel (9 out of 10 patents)

bronzeMedal Jeffrey Kroll Adams (9 out of 15 patents)

4.  Yaron Ilan (9 out of 47 patents)

5.  Elazar S Rabbani (6 out of 122 patents)

6.  James J Donegan (5 out of 84 patents)

7.  Dakai Liu (5 out of 28 patents)

8.  Maya Margalit (4 out of 4 patents)

9.  Joshua Rabbani (3 out of 14 patents)

10.  Xiaofeng Li (3 out of 17 patents)

11.  Eran Elinav (3 out of 5 patents)

12.  Ari Zimran (2 out of 3 patents)

13.  Dean L Engelhardt (2 out of 18 patents)

14.  James G Wetmur (2 out of 7 patents)

15.  Robin S Quartin (2 out of 3 patents)


Core Competencies:
Wnt Pathway Proteins
Sphingosine Kinase Type 1
Glucocerebroside
Bone Loss Treatment
Psoriasis Treatment
Leptin Levels
Viral Vectors
Synthetic Glycolipids
Biomarkers for Lymphoma
Therapeutic Drugs
Nucleic Acid Displacer
Retroviral Vectors

31 patents:

1. 11938167 - Pharmaceutical compositions and methods targeting Wnt pathway proteins (2024-03-26),
2. 11737992 - Sphingosine kinase Type 1 inhibitors and uses thereof (2023-08-29),
3. 11167011 - Methods for treating bone loss using sclerostin peptides (2021-11-09),
4. 10945971 - Sphingosine kinase type 1 inhibitors and uses thereof (2021-03-16),
5. 10723797 - Methods for treating psoriasis (2020-07-28),
6. 10639324 - Glucocerebroside treatment of disease (2020-05-05),
7. 10624863 - Sphingosine kinase type 1 inhibitors and uses thereof (2020-04-21),
8. 10456370 - Sphingosine kinase type 1 inhibitors and uses thereof (2019-10-29),
9. 10328120 - Pharmaceutical compositions targeting WNT pathway proteins (2019-06-25),
10. 10166204 - Sphingosine kinase type 1 inhibitors and uses thereof (2019-01-01),
11. 9974758 - Sphingosine kinase type 1 inhibitors and uses thereof (2018-05-22),
12. 9907810 - Glucocerebroside treatment of liver disorders (2018-03-06),
13. 9744185 - Glucocerebroside treatment of liver disorders (2017-08-29),
14. 9717754 - Glucocerebroside treatment of disease (2017-08-01),
15. 9388121 - Sphingosine kinase type 1 inhibitors (2016-07-12),
Company Overview
Enzo Therapeutics, Inc. is a biotechnology company based in Farmingdale, NY, specializing in the development of innovative therapeutic solutions. The organization focuses on advancing research in molecular diagnostics and therapeutic applications, particularly in the fields of oncology and infectious diseases. Enzo Therapeutics leverages its proprietary technologies to create products that aim to improve patient outcomes and enhance the understanding of complex biological systems.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Enzo Therapeutics, Inc. USPTO Patent Assignee Logo
31 Patents

#9 in Farmingdale, NY

#654 in New York

#10,927 in US

#21,260 in the World

Farmingdale, NY (US)
Farmingdale, NY, United States of America

Enzo Therapeutics, Inc.

Forward Citations = 158

25 inventors:

goldMedal Robert Elliot Zipkin (9 out of 13 patents)

silverMedal Sarah Spiegel (9 out of 10 patents)

bronzeMedal Jeffrey Kroll Adams (9 out of 15 patents)

4.  Yaron Ilan (9 out of 47 patents)

5.  Elazar S Rabbani (6 out of 122 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Enzo Therapeutics, Inc.. Retrieved from https://idiyas.com/company/enzo-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…